Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 13/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18961622 | 0.80 | PKM (0.45) | SLC6A2SLC6A4ALDH1A1MEN1POLB | |
| SCHEMBL18908266 | 0.77 | KCNH2 (0.32) | MEN1KMT2ANPSR1 | |
| SCHEMBL18908288 | 0.77 | KCNH2 (0.32) | MEN1KMT2ANPSR1 | |
| SCHEMBL16316041 | 0.77 | NPSR1 (0.41) | SLC6A2SLC6A4ALDH1A1GAAMEN1 | |
| SCHEMBL1941962 | 0.75 | ALDH1A1 (0.47) | SLC6A2SLC6A4ALDH1A1GAAMEN1 | |
| SCHEMBL10263254 | 0.74 | L3MBTL1 (0.50) | ALDH1A1HPGD | |
| SCHEMBL19304392 | 0.72 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16892264 | 0.69 | ALDH1A1 (0.53) | SLC6A2SLC6A4ALDH1A1GAAMEN1 | |
| SCHEMBL22502082 | 0.69 | L3MBTL1 (0.53) | ALDH1A1HPGD | |
| SCHEMBL29378554 | 0.69 | L3MBTL1 (0.53) | ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT1 | SLC6A2 3992/4885SLC6A4 3844/4885ALDH1A1 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.